REG-4basebio Plc: Director/PDMR Shareholding

4BasebioAnnouncement

13/07/2022 07:15

13 July 2022

4basebio plc
(the "Company")
 

Director’s Dealing

4basebio PLC (AIM: 4BB), the specialist life sciences group focused on
exploiting intellectual property in the field of cell and gene therapies and
DNA vaccines, announces that it was notified on 12 July 2022 that Dr Heikki
Lanckriet, chief executive officer, on the same day transferred 29,000
ordinary shares at a price of 415 pence per share from his personal holding
into his SIPP (the “Transfer”).

Following the Transfer, there is no change to Dr Heikki Lanckriet’s
beneficial holding, and his interest in the Company remains at 1,252,453
Ordinary Shares, representing approximately 10.17% of the Company's issued
share capital.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.

For further enquiries, please contact:

 4basebio plc                                        +44 (0)12 2396 7943 
 Heikki Lanckriet, CEO                                                   
                                                                         
 Cairn Financial Advisers LLP (Nominated Adviser )   +44 (0)20 7213 0880 
 Jo Turner / Sandy Jamieson                                              
                                                                         
 finnCap Ltd (Broker)                                +44 (0)20 7220 0500 
 Geoff Nash/Richard Chambers/Charlotte Sutcliffe                         
                                                                         

   

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014                                                                                                                                                                                   
 1   Details of the person discharging managerial responsibilities/person closely associated                                                                                                                                                                               
 a.  Name                                                                              Dr Heikki Lanckriet                                                                                                                                                                 
 2   Reason for notification                                                                                                                                                                                                                                               
 a.  Position/Status                                                                   Chief Executive Officer                                                                                                                                                             
 b.  Initial notification/ Amendment                                                   Initial Notification                                                                                                                                                                
 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                                                                                         
 a.  Name                                                                              4basebio plc                                                                                                                                                                        
 b.  LEI                                                                               213800E2DX9EAIUNCB30                                                                                                                                                                
 4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted                                                                     
 a.  Description of the financial instrument, type of instrument  Identification Code  Ordinary shares   ISIN: GB00BMCLYF79                                                                                                                                                
 b.  Nature of the transaction                                                         Transfer from nominee account to SIPP                                                                                                                                               
 c.  Price(s) and volume(s)                                                                                                                                                                                                                                                
                                                                                                                     Price(s) per share (p)        Volume(s)                                                                                                               
     415p                                                                                                            29,000                                                                                                                  
                                                                                                                                                                                                                     
 d.  Aggregated information                                                            * 29,000                                                                                                                                                                            
                                                                                       * 415 pence per share                                                                                                                                                               
 e.  Date of the transaction                                                           12/07/2022                                                                                                                                                                          
 f.  Place of the transaction                                                          London Stock Exchange, AIM                                                                                                                                                          



Copyright (c) 2022 PR Newswire Association,LLC. All Rights Reserved